Show simple item record

dc.contributor.advisorUgarte Gil, César Augusto
dc.contributor.authorChanamé-Baca, Diego*
dc.date.accessioned2018-02-15T01:43:25Z
dc.date.available2018-02-15T01:43:25Z
dc.date.issued2018-02-01
dc.identifier.citation1. Echecopar-Sabogal J, D’Angelo-Piaggio L, Chanamé-Baca DM, Ugarte-Gil C. Association between the use of protease inhibitors in highly active antiretroviral therapy and incidence of diabetes mellitus and/or metabolic syndrome in HIV-infected patients: A systematic review and meta-analysis [Internet]. International Journal of STD & AIDS. Universidad Peruana de Ciencias Aplicadas (UPC); 2017. Available from: http://hdl.handle.net/10757/622684es_PE
dc.identifier.urihttp://hdl.handle.net/10757/622684
dc.description.abstractIntroduction: Despite the advances in increasing life expectancy among people living with HIV/AIDS, Highly Active Antiretroviral Treatment (HAART) use and HIV infection itself have been associated with the occurrence of Type 2 Diabetes Mellitus (DM), specifically with the use of protease inhibitors (PIs). The aim of this systematic review was to determine if there is an association between the use of PIs and the incidence of DM in HIV-infected patients. Methods: A systematic literature search was performed using MEDLINE/PubMed, CENTRAL, LILACS and EMBASE. Included articles were observational studies published on or prior to November 2015 that met the following criteria: study population comprised HIV-infected patients aged 18 years or older and who were receiving HAART; patients assessed according to their use of PIs; DM were defined in the study and described during follow-up. Studies were selected independently by two investigators. Pooled relative risks (RR) and hazard ratios (HR) were calculated. Heterogeneity was assessed by New Castle Ottawa Scale (NOS) for nonrandomized studies and The Cochrane Collaboration’s Tool for assessing risk of bias for randomized trials. Results: 13155 HIV patients in 6 studies were included. All studies used HR as association measure and only 1 study used RR. Length of follow-up varied between 3 years to 17 years. No association between the use of PIs and development of DM was found: the HR for the incidence of DM among patients using PIs was 1.23 (95% CI 0.66 to 2.30; p-value: 0.51) and the RR was 1.25 (95% CI 0.99 to 1.58; p-value 0.06). Conclusion: No evidence of an increased risk of DM was found. However, the length of follow-up could be short to evaluate DM incidence, requiring a longer follow-up in order to detect an association between PI use and onset of DM.
dc.description.uriTesises_PE
dc.formatapplication/pdfes
dc.formatapplication/epubes
dc.formatapplication/mswordes
dc.language.isospaes
dc.publisherUniversidad Peruana de Ciencias Aplicadas (UPC)es
dc.rightsinfo:eu-repo/semantics/embargoedAccesses
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceUniversidad Peruana de Ciencias Aplicadas (UPC)es_PE
dc.sourceRepositorio Académico - UPCes_PE
dc.subjectVIHes_PE
dc.subjectDiabetes mellituses_PE
dc.subjectInhibidor de la proteasaes_PE
dc.subjectRevisión sistemáticaes_PE
dc.subjectMetaanálisises_PE
dc.subjectHAARTes_PE
dc.subjectMedicinaes_PE
dc.titleAssociation between the use of protease inhibitors in Highly Active Antiretroviral Therapy (HAART) and incidence of diabetes mellitus in HIV-infected patients: A systematic review and meta-analysises
dc.typeinfo:eu-repo/semantics/bachelorThesises
thesis.degree.grantorUniversidad Peruana de Ciencias Aplicadas (UPC). Facultad de Ciencias de la Saludes_PE
thesis.degree.levelLicenciaturaes_PE
thesis.degree.disciplineMedicinaes_PE
thesis.degree.nameMédico cirujanoes_PE
refterms.dateFOA2018-06-19T09:30:50Z
html.description.abstractIntroduction: Despite the advances in increasing life expectancy among people living with HIV/AIDS, Highly Active Antiretroviral Treatment (HAART) use and HIV infection itself have been associated with the occurrence of Type 2 Diabetes Mellitus (DM), specifically with the use of protease inhibitors (PIs). The aim of this systematic review was to determine if there is an association between the use of PIs and the incidence of DM in HIV-infected patients. Methods: A systematic literature search was performed using MEDLINE/PubMed, CENTRAL, LILACS and EMBASE. Included articles were observational studies published on or prior to November 2015 that met the following criteria: study population comprised HIV-infected patients aged 18 years or older and who were receiving HAART; patients assessed according to their use of PIs; DM were defined in the study and described during follow-up. Studies were selected independently by two investigators. Pooled relative risks (RR) and hazard ratios (HR) were calculated. Heterogeneity was assessed by New Castle Ottawa Scale (NOS) for nonrandomized studies and The Cochrane Collaboration’s Tool for assessing risk of bias for randomized trials. Results: 13155 HIV patients in 6 studies were included. All studies used HR as association measure and only 1 study used RR. Length of follow-up varied between 3 years to 17 years. No association between the use of PIs and development of DM was found: the HR for the incidence of DM among patients using PIs was 1.23 (95% CI 0.66 to 2.30; p-value: 0.51) and the RR was 1.25 (95% CI 0.99 to 1.58; p-value 0.06). Conclusion: No evidence of an increased risk of DM was found. However, the length of follow-up could be short to evaluate DM incidence, requiring a longer follow-up in order to detect an association between PI use and onset of DM.
renati.typehttp://purl.org/pe-repo/renati/type#tesises_PE
renati.levelhttp://purl.org/pe-repo/renati/nivel#tituloProfesionales_PE
dc.publisher.countryPEes_PE
dc.type.otherTesises_PE


Files in this item

Thumbnail
Name:
Chanamé_BD.pdf
Size:
339.4Kb
Format:
PDF
Thumbnail
Name:
Chanamé_BD.epub
Size:
492.5Kb
Format:
application/epub
Thumbnail
Name:
Chanamé_BD.docx
Embargo:
2087-02-01
Size:
1.347Mb
Format:
Microsoft Word 2007
Thumbnail
Name:
Chanamé_BD_ficha.pdf
Embargo:
2087-02-01
Size:
97.38Kb
Format:
PDF

This item appears in the following Collection(s)

  • Medicina [576]
    Tesis del Priograma Académico de Medicina

Show simple item record

info:eu-repo/semantics/embargoedAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/embargoedAccess